Attach to Form 990 or Form 990-EZ.
Go to
www.irs.gov/Form990 for instructions and the latest information.
| (i) Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 10 above (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
|
Total |
||||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2020 | (b) 2021 | (c) 2022 | (d) 2023 | (e) 2024 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") .. | ||||||
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf .... | ||||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 4 | Total. Add lines 1 through 3 | ||||||
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f) .. | ||||||
| 6 | Public support. Subtract line 5 from line 4. | ||||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2020 | (b) 2021 | (c) 2022 | (d) 2023 | (e) 2024 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | ||||||
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | ||||||
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | ||||||
| 11 | Total support. Add lines 7 through 10 | ||||||
Calendar year (or fiscal
year beginning in) ![]() |
(a) 2020 | (b) 2021 | (c) 2022 | (d) 2023 | (e) 2024 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | 2,118,700 | 1,004,262 | 982,259 | 634,787 | 1,331,631 | 6,071,639 |
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513 ..... | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge | ||||||
| 6 | Total. Add lines 1 through 5 | 2,118,700 | 1,004,262 | 982,259 | 634,787 | 1,331,631 | 6,071,639 |
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public support. (Subtract line 7c from line 6.) | 6,071,639 | |||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2020 | (b) 2021 | (c) 2022 | (d) 2023 | (e) 2024 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | 2,118,700 | 1,004,262 | 982,259 | 634,787 | 1,331,631 | 6,071,639 |
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | 1,157 | 2,348 | 5,456 | 6,584 | 10,408 | 25,953 |
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | 1,157 | 2,348 | 5,456 | 6,584 | 10,408 | 25,953 |
| 11 | Net income from unrelated business activities not included on line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | ||||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | 2,119,857 | 1,006,610 | 987,715 | 641,371 | 1,342,039 | 6,097,592 |
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e |
Discount claimed for blockage or other factors (explain in detail in Part VI): |
|||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 0.015 of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by 0.035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | 1 | |
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
2 | |
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | 3 | |
| 4 Amounts paid to acquire exempt-use assets | 4 | |
| 5 Qualified set-aside amounts (prior IRS approval required - provide details in Part VI) | 5 | |
| 6 Other distributions (describe in Part VI). See instructions | 6 | |
| 7Total annual distributions. Add lines 1 through 6. | 7 | |
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
8 | |
| 9 Distributable amount for 2024 from Section C, line 6 | 9 | |
| 10 Line 8 amount divided by Line 9 amount | 10 | |
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2024 |
(iii) Distributable Amount for 2024 |
|
|---|---|---|---|---|
| 1 Distributable amount for 2024 from Section C, line 6 | ||||
|
2
Underdistributions, if any, for years prior to 2024 (reasonable cause required-- explain in Part VI).
See instructions. |
||||
| 3 Excess distributions carryover, if any, to 2024: | ||||
| a From 2019....... | ||||
| b From 2020....... | ||||
| c From 2021....... | ||||
| d From 2022....... | ||||
| e From 2023....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2024 distributable amount | ||||
|
i
Carryover from 2019 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from line 3f. | ||||
| 4Distributions for 2024 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2024 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from line 4. | ||||
|
5
Remaining underdistributions for years prior to 2024, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
6
Remaining underdistributions for 2024. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
7 Excess distributions carryover to 2025. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a Excess from 2020..... | ||||
| b Excess from 2021..... | ||||
| c Excess from 2022..... | ||||
| d Excess from 2023..... | ||||
| e Excess from 2024..... | ||||
| Facts And Circumstances Test |
|---|
| Return Reference | Explanation |
|---|
| Software ID: | |
| Software Version: |
| Return Reference | Explanation |
|---|---|
| FORM 990 - ORGANIZATION'S MISSION | THE RP FOUNDATION'S MISSION IS TO: (A) INCREASE AWARENESS ABOUT RELAPSING POLYCHONDRITIS; (B) PROVIDE SUPPORT (PRIMARILY THROUGH THE USE OF THE INTERNET, SOCIAL MEDIA, AND PATIENT ADVOCACY PROGRAMS) FOR THOSE WHO ARE AFFECTED BY RELAPSING POLYCHONDRITIS, SUPPORT RESEARCH TO ADVANCE A CURE FOR RELAPSING POLYCHONDRITIS; (C) PROMOTE QUALITY CARE FOR RELAPSING POLYCHONDRITIS PATIENTS; AND (D) ENGAGE IN SUCH OTHER ACTIVITIES IN CONNECTION THEREWITH THAT THE BOARD OF DIRECTORS MAY AUTHORIZE, IN ALL CASES SUBJECT TO THE PROVISION OF SECTION 501(C)(3) OF THE INTERNAL REVENU CODE OF 1986, AS AMENDED, OR THE CORRESPONDING PROVISIONS OF ANY SUBSEQUENT FEDERAL TAX LAW (THE "CODE"). |
| FORM 990, PAGE 2, PART III, LINE 4A | AWARENESS: THE RP FOUNDATION AMPLIFIED ITS MISSION TO THE BROADER COMMUNITY THROUGH STRATEGIC PARTNERSHIPS, INCLUDING COLLABORATION WITH RACE FOR RP AND SIX INTERNATIONAL MOTORSPORTS TEAMS. THIS INCLUDED THE CREATION OF THE AWARD- WINNING "RACE OF OUR LIVES DOCUMENTARY" IN 2023. THE DOCUMENTARY, A SEQUEL TO THE 2018 "RIDE OF MY LIFE" FILM, RECEIVED MULTIPLE ACCOLADES IN FY25, INCLUDING BEST DOCUMENTARY FEATURE AT THE LOS ANGELES MOVIE AWARDS AND THE SOCAL FILM AWARDS. FOCUSED ON A PATIENT'S JOURNEY WITH RELAPSING POLYCHONDRITIS, THE FILM WAS PRAISED FOR ITS POWERFUL STORYTELLING. CONCURRENTLY, THE FOUNDATION SIGNIFICANTLY INCREASED AWARENESS AND SUPPORT FOR ITS INNOVATIVE RP AND AUTOIMMUNE RESEARCH THROUGH ROBUST DIGITAL COMMUNICATIONS, UTILIZING PLATFORMS LIKE YOUTUBE, ENEWSLETTER, AND SOCIAL MEDIA CHANNELS (X, FACEBOOK, AND INSTAGRAM). THESE EFFORTS RESULTED IN SUBSTANTIAL FOLLOWER GROWTH ACROSS ALL SOCIAL MEDIA PLATFORMS. |
| FORM 990, PAGE 2, PART III, LINE 4B | RESEARCH: THE RP FOUNDATION'S COMMITMENT TO ADVANCING RESEARCH IN RELAPSING POLYCHONDRITIS (RP) AND RELATED AUTOIMMUNE DISEASES YIELDED SIGNIFICANT PROGRESS IN FY25. THROUGH THE FOUNDATION'S ONGOING FINANCIAL SUPPORT, THE PENN MEDICINE RP PROGRAM NOT ONLY PROVIDED HIGHLY INDIVIDUALIZED, MULTIDISCIPLINARY CARE TO RP PATIENTS BUT ALSO SIGNIFICANTLY EXPANDED ITS RESEARCH INFRASTRUCTURE. THE PROGRAM'S COLLABORATION WITH THE VASCULITIS CLINICAL RESEARCH CONSORTIUM (VCRC) LONGITUDINAL STUDY PROVED VITAL IN GROWING BOTH ITS CLINICAL AND RESEARCH ENDEAVORS. KEY RESEARCH ACTIVITIES IN FY25 INCLUDED: "THE NASAL MICROBIOME IN ANCA ASSOCIATED VASCULITIS AND RELAPSING POLYCHONDRITIS (NMB) STUDY. "THE PROSPECT CLINICAL TRIAL (NCT06941376) - A PILOT STUDY EXAMINING IMMUNOMODULATORY MEDICATIONS FOR RP. A MAJOR DEVELOPMENT IN FY25 WAS THE ESTABLISHMENT OF THE REDEFINING AUTOIMMUNE DISEASES ACROSS RHEUMATOLOGY (RADAR) RP PROGRAM, FOCUSED ON CHARACTERIZING AUTOIMMUNITY IN RP PATIENTS. THIS PROGRAM HOLDS THE PROMISE OF ACCELERATING DIAGNOSES, TAILORING TREATMENTS, AND DEVELOPING INNOVATIVE TARGETED IMMUNOTHERAPIES FOR RP BY IDENTIFYING CRITICAL INFLAMMATORY CELLS AND SERUM MARKERS. FURTHER UNDERSCORING ITS DEDICATION, THE RP FOUNDATION INVESTED IN AN RP FELLOW AT PENN MEDICINE TO FURTHER SPECIALIZED RP RESEARCH, ULTIMATELY AIMING TO CULTIVATE AN RO1-LEVEL RELAPSING POLYCHONDRITIS RESEARCHER. THE RP FOUNDATION PLAYED A CRUCIAL ROLE IN THE SUCCESSFUL LAUNCH AND CONTINUED GROWTH OF THE PURPOSE BIOBANK AT ALLEGHENY HEALTH NETWORK, WHICH BEGAN IN 2024. IN FISCAL YEAR 2025 ALONE, THE BIOBANK WELCOMED 106 PARTICIPANTS FROM 24 STATES AND PUERTO RICO, INCLUDING 66 PATIENTS WITH RP. THIS LED TO THE COLLECTION OF 88 BLOOD SAMPLES, WHICH ARE NOW STORED FOR VITAL FUTURE RESEARCH INTO RP AND RELATED AUTOIMMUNE DISEASES. |
| FORM 990, PAGE 2, PART III, LINE 4C | EDUCATION: THE RP FOUNDATION AND RACE FOR RP ARE INSPIRED BY THE COURAGE AND RESILIENCE OF INDIVIDUALS WITH RELAPSING POLYCHONDRITIS (RP). THROUGH A RAPIDLY EXPANDING NETWORK OF PATIENTS, DONORS, AND RESEARCHERS, UNIQUE OPPORTUNITIES ARE CREATED TO ADVANCE DISCOVERIES IN RP AND RELATED AUTOIMMUNE DISEASES. IN FY25, THE PENN DIVISION OF RHEUMATOLOGY AND RP PROGRAM, WITH RP FOUNDATION SUPPORT, HELD AN EDUCATIONAL MEETING FOR RP PATIENTS AND THEIR FAMILIES, FACILITATING COMMUNITY BUILDING, EXPERT INTERACTION, AND LEARNING ABOUT RP. THE RP FOUNDATION HIGHLIGHTED ITS RP- FOCUSED RESEARCH INVESTMENTS AND PENN COLLABORATION AT THIS MEETING IN OCTOBER 2024. FURTHERMORE, THE PENN VASCULITIS CENTER / PENN RP PROGRAM, WITH SUPPORT FROM THE RP FOUNDATION AND OTHER PARTNERS, HOSTED DR. ROGER YANG, A VASCULITIS FOUNDATION FELLOW. DR. YANG PROVIDED PATIENT CARE AND WAS INSTRUMENTAL IN CONTRIBUTING TO THE VCRC'S DATABASE REGARDING THE CLINICAL CHARACTERISTICS OF RP AND TREATMENT APPROACHES. HE INTENDS TO OPEN A NEW ACADEMIC VASCULITIS CENTER IN MONTREAL, WHERE HE WILL CONTINUE TO CARE FOR RP PATIENTS. |
| FORM 990, PAGE 2, PART III, LINE 4D | FUNDRAISING IN FY25, THE RELAPSING POLYCHONDRITIS (RP) FOUNDATION'S DEDICATION TO ADVANCING RESEARCH WAS UNDERSCORED BY A SERIES OF SUCCESSFUL FUNDRAISING INITIATIVES AND THE ACHIEVEMENT OF GUIDESTAR'S PLATINUM SEAL OF TRANSPARENCY. THESE EFFORTS DIRECTLY FUEL BREAKTHROUGHS IN RP AND RELATED AUTOIMMUNE DISEASE RESEARCH. HIGHLIGHTS OF FUNDRAISING IN FY25 INCLUDE: -GROWING THE COMMUNITY THROUGH ANNUAL GIVING TUESDAY AND END-OF-YEAR APPEALS -RP WARRIOR 5K WALK: THIS GLOBAL, PATIENT-LED EVENT MOBILIZED INDIVIDUALS TO SUPPORT VITAL RELAPSING POLYCHONDRITIS RESEARCH. -EXCLUSIVE 2025 VIP RACE WEEKEND AT THE INDIANAPOLIS 500: THIS EVENT, THANKS TO RP FOUNDATION PARTNERS KEVIN LEE AND JAMES HINCHCLIFFE, PROVIDED UNFORGETTABLE EXPERIENCES FOR ATTENDEES WHILE RAISING SIGNIFICANT FUNDS FOR RP-RELATED AUTOIMMUNE DISEASE RESEARCH. VIP ACCESS TO EVENTS LIKE THE LEGENDS DAY DRIVERS MEETING AND PRE-RACE REHEARSAL, ALONG WITH A VIP GARAGE TOUR AND AUTOGRAPH SESSION, ENHANCED THE EXPERIENCE. A CARB NIGHT HAPPY HOUR WITH JAMES HINCHCLIFF AND FRIENDS FURTHER CONTRIBUTED TO THE STOP AND GO FOUNDATION, THE RELAPSING POLYCHONDRITIS FOUNDATION, AND AUTOIMMUNE DISEASE RESEARCH. -MCLAREN TROPHY VIP EXPERIENCE COMPETITION: THIS PARTNERSHIP WITH MCLAREN PROVIDED A UNIQUE WAY FOR EMPLOYEES TO SUPPORT RP RESEARCH THROUGH DONATIONS AND A CHANCE TO ACQUIRE EXCLUSIVE RACE DAY TICKETS. THESE ACCOMPLISHMENTS REFLECT THE RP FOUNDATION'S TANGIBLE IMPACT IN ALL AREAS OF ITS PURPOSE. GRATITUDE IS EXTENDED TO THE CLINICAL RESEARCH PARTNERS FOR THEIR CONTINUOUS EFFORTS IN DRIVING DISCOVERIES AND ADVANCEMENTS IN RP AND RELATED AUTOIMMUNE DISEASES. WITH CONTINUED SUPPORT, THE RP FOUNDATION REMAINS COMMITTED TO BEING A SOURCE OF HOPE AND A DRIVING FORCE FOR RESEARCH THAT WILL ULTIMATELY LEAD TO EFFECTIVE TREATMENTS AND A CURE FOR RP. |
| FORM 990, PAGE 6, PART VI, LINE 11B | THE FORM 990 IS PROVIDED TO THE BOARD WHICH IS REVIEWED AND DISCUSSED AT A MEETING. |
| FORM 990, PAGE 6, PART VI, LINE 12C | POLICY IS EMAILED, SIGNED BY MEMBERS AND RETAINED BY TREASURER. THIS IS DONE ANNUALLY. |
| FORM 990, PAGE 6, PART VI, LINE 15A | AN INFORMAL MARKET SURVEY REGARDING PAY RATES AND RESPONSIBILITIES FOR EQUIVALENT DIRECTOR POSITIONS IN SIMILAR NON-PROFIT ORGANIZATIONS WAS PERFORMED. THE RESPONSIBILITIES/ACCOMPLISHMENTS OF THE CURRENT CONTRACTUAL DIRECTOR/PRESIDENT WAS REVIEWED. COMPENSATION WAS BASED ON THE BOARD DISCUSSION AND MARKET SURVEY. |
| FORM 990, PAGE 6, PART VI, LINE 15B | SEE RESPONSE TO 15A. THERE ARE NO OTHER EMPLOYEES. |
| FORM 990, PAGE 6, PART VI, LINE 18 | ALSO AVAILABLE ON WWW.GUIDESTAR.ORG |
| FORM 990, PAGE 6, PART VI, LINE 19 | GOVERNING DOCUMENTS ARE AVAILABLE ON REQUEST. |
| Software ID: | |
| Software Version: |